Concepedia

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Esther Natalie Olíva, Caterina Alati, Valeria Santini, Antonella Poloni, Alfredo Molteni, Pasquale Niscola, Flavia Salvi, Grazia Sanpaolo, Enrico Balleari, Ulrich Germing,

The Lancet Haematology · 2017 · 162 citations · 20 references

DOIFull text

Open access

Concepts

References

20

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 16K citations

, , +15

Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al. · American Journal of Clinical Oncology · 1982 · 11.6K citations

, , +8

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg, Heinz Tuechler, Julie Schanz et al. · Blood · 2012 · 3.1K citations · Full text

, , +12

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

Bruce D. Cheson · Blood · 2006 · 1.6K citations

, , +9

Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia

Matthew J. Olnes, Phillip Scheinberg, Katherine R. Calvo et al. · New England Journal of Medicine · 2012 · 538 citations · Full text

, , +9